PTO changes on biotech patents
Executive Summary
Patent & Trademark Office will publish examples of patent claim sets as references for avoiding "restriction" requirements in approximately six months. The move is part of a five-point plan to address when and how patent examiners limit or restrict the number of inventions in a single application for biotech, pharmaceutical and organic chemistry patents. PTO says it also will train examiners to analyze and recognize claim sets that should be examined together and will implement "a 'second pair of eyes' to review restriction decisions made by examiners to promote consistency." Biotechnology Industry Organization, which has been pushing for changes in restriction practice, called PTO's announcement a "positive step" but says a legislative change in the PTO's fee structure is still needed...
You may also be interested in...
News We’re Watching: AI Safety Partnership; Boston Scientific Recalls; New Cancer, STI Tests; VR
This week, the US and UK announced a partnership to promote AI safety. Boston Scientific recalls embolic agent. LumiCell received FDA approval for its imaging agent to detect residual cancer. Scout receives an award to develop an STI test; and Osso VR leverages the Apple Vision Pro for VR medical training.
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.
Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development
Pink Sheet editors discuss Medicare spending projections for the Alzheimer’s treatment Leqembi, Janet Woodcock’s new post-FDA role, and ongoing preparations for new pneumococcal vaccines that will reach the market soon.